Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study

Jia Horng Kao, Min Lung Yu, Chi Yi Chen, Cheng Yuan Peng, Ming Yao Chen, Huoling Tang, Qiaoqiao Chen, Jinzi J. Wu

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background and Aim: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) patients without cirrhosis. Methods: A total of 38 treatment-naïve, non-cirrhotic adult HCV GT1 patients were enrolled in this multicenter, open-label, single-arm phase 2 study (NCT03020095). All patients received a combination of RDV 200 mg once daily (q.d.) plus DNVr 100 mg/100 mg twice daily (b.i.d.) and oral RBV 1000/1200 mg/day (body weight < 75/≥ 75 kg) for 12 weeks. The primary endpoint was the rate of sustained virologic response 12 weeks after the end of treatment (SVR12). Results: Of 38 patients, all (100%) achieved SVR12. During the study, no treatment-related serious adverse events, no patients discontinued treatment due to adverse events, and no deaths were reported. Six of 37 (16%) patients with available sequences had HCV NS5A resistance-associated variants at baseline. All patients (6/6) with baseline NS5A resistance-associated variants achieved SVR12. Conclusions: Twelve-week RDV and DNVr in combination with RBV for 12 weeks achieves the SVR12 rate of 100% in treatment-naïve non-cirrhotic Asian patients with HCV GT1 infection. This interferon-free regimen is also safe and well tolerated.

Original languageEnglish
Pages (from-to)1507-1510
Number of pages4
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Keywords

  • danoprevir
  • efficacy
  • hepatitis C
  • interferon free
  • ravidasvir
  • Administration, Ophthalmic
  • Humans
  • Middle Aged
  • Male
  • Time Factors
  • Aged, 80 and over
  • Adult
  • Female
  • Hepatitis C, Chronic/drug therapy
  • Drug Therapy, Combination
  • Sulfonamides/administration & dosage
  • Drug Administration Schedule
  • Hepacivirus/genetics
  • Ritonavir/administration & dosage
  • Genotype
  • Treatment Outcome
  • Antiviral Agents
  • Liver Cirrhosis
  • Lactams/administration & dosage
  • Asian Continental Ancestry Group
  • Ribavirin/administration & dosage
  • Aged

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study'. Together they form a unique fingerprint.

Cite this